logo
Plans to tackle mental health crisis 'not ambitious enough', charity boss tells Sky News

Plans to tackle mental health crisis 'not ambitious enough', charity boss tells Sky News

Yahoo2 days ago

Government plans to strengthen mental health services are "not ambitious enough", a charity head has told Sky News.
Dr Sarah Hughes, chief executive of mental health charity Mind, spoke to The UK Tonight with Sarah-Jane Mee after a report on mental health cases at A&E reaching crisis levels.
Sky's health correspondent Ashish Joshi reported that waiting times for these cases have risen, and overnight beds in mental health units are down almost 3,700 in a decade.
Dr Hughes called the report "incredibly important insight into what's happening," before adding: "One of our wonderful campaigners waited 87 hours on a stretcher when she was incredibly distressed.
"These are scenes are happening up and down the country, and I'm afraid to say that whilst I'm devastated to see them, I'm not surprised."
She then said that while "there are all sorts of services" across the UK for mental health, they are "nowhere near the level that we need".
'We know what works'
"We are seeing thousands and thousands of people go into A&E every month for very serious mental health challenges, and this can be resolved quite easily by beefing up what's available in the community," Dr Hughes said.
"By making sure that community mental health services are resourced so that people are caught far earlier, that we don't hit crisis, that they're able to get the support they need well before they get into trouble.
"We know what works: We know that with proper investment that we could avoid this situation."
The charity boss also said that while new initiatives from the government on services would be welcomed, "fundamentally, without mental health support, we're not enabling [people] to thrive".
"In fact," she said, "we're putting them into incredibly vulnerable situations day in day out. They are carrying the risk here.
"We know that mental health staff in A&Es are also really struggling. They want to do a good job, and they can't. They're not resourced to."
Plans to tackle spike in cases 'not ambitious enough'
New Freedom of Information data gathered by the Royal College of Nursing shows that over the last five years, waits of 12 hours or more for a mental health bed have increased by more than 380%.
When asked about whether and government plans will help tackle the sharp rise, Dr Hughes said: "We already know that they don't and they won't.
"We are expecting a real-terms cut in terms of the funding around mental health going forward. We are not convinced or persuaded that we've got the share of spend that's right for mental health.
"We're concerned that the plans for mental health are not ambitious enough. We're not really persuaded, I think, that the policies surrounding mental health either are going to help reform and so on.
"All of these things that are going on demonstrate a lack of understanding."
Read more from Sky News:
In response to Ashish Joshi's report, the Department for Health and Social Care told Sky News: "We know people with mental health issues are not always getting the support or care they deserve and incidents like this are unacceptable.
"We are transforming mental health services - including investing £26m to support people in mental health crisis, hiring more staff, delivering more talking therapies, and getting waiting lists down through our Plan for Change."

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

One thing we can count on to keep ruining our summers
One thing we can count on to keep ruining our summers

Vox

time31 minutes ago

  • Vox

One thing we can count on to keep ruining our summers

is a correspondent at Vox writing about climate change, energy policy, and science. He is also a regular contributor to the radio program Science Friday. Prior to Vox, he was a reporter for ClimateWire at E&E News. Smoke from wildfires in Canada is once again shrouding parts of the United States — cities like Chicago and Milwaukee — with unhealthy air, according to the US Environmental Protection Agency. Parts of the plume have reached as far as Europe. The bulk of the smoke is forecasted to drift eastward across North America and thin out. As of Thursday afternoon, Canada was battling more than 200 blazes, the majority in western provinces like British Columbia and Alberta, according to the Canadian Interagency Forest Fire Centre. In Canada, the fires forced more than 27,000 people to evacuate, but the smoke is 'impacting aerial operations for both suppression and evacuation flights.' This is all too familiar. Canada faced a massive spate of wildfires in 2023 and in 2024 that similarly sent clouds of ash and dust across North America, reaching places like New York City. The burned area this year is a fraction of the size of the regions scorched in 2023, a record-breaking year for wildfires in Canada, but it's still early in the fire season. Canadian fire officials warn that the 'potential for emerging significant wildland fires is high to extreme' and lightning may lead to more ignitions in the next few days. These blazes remind us that the dangers of wildfires reach far beyond their flames, and the threat is growing. Wildfire smoke contains a melange of gases like carbon monoxide, particles of soot, and hazardous chemicals like polycyclic aromatic hydrocarbons that can cause cancer. The tiniest particles in smoke can penetrate deep into the lungs, and even reach the bloodstream, leading to a variety of health problems. When it drifts over a community, it often causes a surge in emergency room visits as people who breathe the smoke suffer strokes, heart attacks, and asthma attacks. There's also evidence that long-term exposure to smoke can lead to a higher likelihood of death from heart, lung, kidney, and digestive diseases. And experts believe the true health burden from wildfires is likely much more extensive than we realize. The harms to health will increase as wildfires become more destructive. Though wildfires are a natural, regular, and vital phenomenon across many landscapes, more people are now living in fire-prone areas, increasing the risk to lives and homes. That increases the odds of starting a fire and means more people and property are in harm's way when one ignites. Decades of fire suppression have allowed fuels like trees and grasses to build up to dangerous levels. And as humanity continues to burn fossil fuels, emitting greenhouse gases and heating up the planet, the climate is changing in ways that enhance fire conditions. So smoke isn't the only pollutant to worry about, and as average temperatures continue to rise, these factors are undoing hard-fought progress in improving air quality across much of the world. However, there are ways to clear the air and avoid some of the worst harms. One tactic is to pay attention to the Air Quality Index in your area and avoid being outdoors when pollution reaches high levels. Wearing a high-quality KN95 or N95 mask can help reduce the damage from polluted air. Blocking air from getting indoors and filtering the air in living areas reduces smoke exposure as well.

Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025
Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025

Yahoo

time2 hours ago

  • Yahoo

Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025

Vivoryon Therapeutics N.V. Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025 Halle (Saale) / Munich, Germany, June 6, 2025 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that meta-analysis data for its lead drug in development, varoglutamstat, was presented at the 62nd ERA Congress of the European Renal Association in Vienna, Austria, today, June 6, 2025. 'We are delighted that the results of the Phase 2 program were accepted for presentation at the ERA 2025 congress. This allowed Vivoryon to share the outstanding improvements of varoglutamstat on kidney function (eGFR) with the scientific and medical expert community in the kidney space,' said Frank Weber, MD, CEO of Vivoryon. Presentation Highlights Varoglutamstat is a first-in-class glutaminyl cyclase (QPCT/L) inhibitor with potent anti-inflammatory and anti-fibrotic effects. VIVIAD and VIVA-MIND, two independent Phase 2 studies in the EU and U.S. showed a statistically significant and clinically meaningful improvement in a prospectively defined kidney function parameter, eGFR, in an elderly patient population. This improvement was consistent in both trials independently, replicated in the meta-analysis and pooled analysis, and provides converging evidence for this finding. Statistically significant differences between varoglutamstat and placebo were first observed at week 24 and were sustained until week 96. The meta-analysis also confirmed a substantially larger effect size in study participants with diabetes compared to those without diabetes. The next step is planned to be a dedicated Phase 2b trial in patients with diabetic kidney disease (patients with diabetes and chronic kidney disease stage 3b/4). The main goal will be to investigate the efficacy on eGFR in this patient population and to obtain additional information on a potential effect on proteinuria and other kidney specific markers. Presentation Details Date: June 6, 2025 Presentation time: 8:15 am CEST as part of the focused oral session Title: Varoglutamstat improves eGFR and offers a new approach to treat diabetic kidney disease (DKD): meta-analysis from two independent Phase 2 studies Venue: Vienna, Austria Presenter: Frank Weber, MD, CEO of Vivoryon Therapeutics ### About Vivoryon Therapeutics N.V. Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for the treatment of inflammatory and fibrotic disorders of the kidney. Driven by its passion for ground-breaking science and innovation, the Company strives to improve patient outcomes by changing the course of severe diseases through modulating the activity and stability of pathologically relevant proteins. Vivoryon's most advanced program, varoglutamstat, a proprietary, first-in-class orally available QPCT/L inhibitor, is being evaluated to treat diabetic kidney disease.

Morten Harket, lead singer of a-ha, has Parkinson's disease
Morten Harket, lead singer of a-ha, has Parkinson's disease

CNN

time4 hours ago

  • CNN

Morten Harket, lead singer of a-ha, has Parkinson's disease

Morten Harket has revealed he has Parkinson's disease. The singer of a-ha, the band behind the 1985 hit and innovatively animated music video 'Take On Me,' shared the news during an interview with the group's biographer. 'I've got no problem accepting the diagnosis,' Harket said. 'With time, I've taken to heart my 94-year-old father's attitude to the way the organism gradually surrenders: 'I use whatever works'.' Harket, 65, explained why he wanted to share his diagnosis publicly. 'Acknowledging the diagnosis wasn't a problem for me; it's my need for peace and quiet to work that has been stopping me. I'm trying the best I can to prevent my entire system from going into decline,' he said. 'It's a difficult balancing act between taking the medication and managing its side effects. There's so much to weigh up when you're emulating the masterful way the body handles every complex movement, or social matters and invitations, or day-to-day life in general.' According to Mayo Clinic, 'Parkinson's disease is a movement disorder of the nervous system that worsens over time.' Harket had 'advanced brain surgery' at the Mayo Clinic, which along with medication, 'have softened the impact of his symptoms,' the a-ha biographer, Jan Omdahl, wrote. 'In June 2024, Morten underwent a neurosurgical procedure in which electrodes were implanted deep inside the left side of his brain. These are connected to a small pacemaker-like device placed under the skin of the upper chest that sends electrical impulses through the electrodes into the brain,' Omdahl wrote. 'The method is called deep brain stimulation (DBS) and is among the most advanced treatments in neurology. The procedure had the desired effect: with the right electrical impulses now reaching Morten's brain, many of his physical symptoms practically vanished. In December 2024 he underwent a similar procedure on the right side of his brain, which was also successful.' Harket's voice, however, has been affected, he said. 'The problems with my voice are one of many grounds for uncertainty about my creative future,' Harket said.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store